Brokers Set Expectations for BPMC FY2027 Earnings

Blueprint Medicines Co. (NASDAQ:BPMC) – Stock analysts at Zacks Research issued their FY2027 EPS estimates for shares of Blueprint Medicines in a report issued on Wednesday, March 5th. Zacks Research analyst A. Chakraborty forecasts that the biotechnology company will earn $3.20 per share for the year. The consensus estimate for Blueprint Medicines’ current full-year earnings is ($1.28) per share.

BPMC has been the topic of a number of other reports. Stephens reaffirmed an “overweight” rating and issued a $140.00 price target on shares of Blueprint Medicines in a research note on Thursday, January 2nd. HC Wainwright reiterated a “buy” rating and set a $135.00 price target on shares of Blueprint Medicines in a report on Friday, February 14th. Wedbush reaffirmed an “outperform” rating and issued a $128.00 target price on shares of Blueprint Medicines in a report on Friday, February 28th. Needham & Company LLC reiterated a “buy” rating and set a $133.00 target price on shares of Blueprint Medicines in a research note on Thursday, February 13th. Finally, JPMorgan Chase & Co. increased their price target on shares of Blueprint Medicines from $126.00 to $129.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $125.21.

Blueprint Medicines Price Performance

Shares of BPMC opened at $87.12 on Thursday. The company has a market capitalization of $5.57 billion, a price-to-earnings ratio of -80.67 and a beta of 0.62. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The business’s 50-day moving average is $99.43 and its 200-day moving average is $94.27. Blueprint Medicines has a fifty-two week low of $80.68 and a fifty-two week high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last released its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in BPMC. Quarry LP bought a new position in shares of Blueprint Medicines during the third quarter worth $32,000. R Squared Ltd bought a new stake in Blueprint Medicines during the 4th quarter worth approximately $51,000. Covestor Ltd increased its position in shares of Blueprint Medicines by 206.7% during the third quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 403 shares in the last quarter. Headlands Technologies LLC acquired a new stake in shares of Blueprint Medicines in the 4th quarter valued at about $65,000. Finally, Thematics Asset Management acquired a new position in Blueprint Medicines during the 4th quarter worth approximately $72,000.

Insider Transactions at Blueprint Medicines

In other Blueprint Medicines news, insider Ariel Hurley sold 1,819 shares of the business’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $93.26, for a total transaction of $169,639.94. Following the completion of the sale, the insider now directly owns 14,967 shares of the company’s stock, valued at approximately $1,395,822.42. The trade was a 10.84 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jeffrey W. Albers sold 15,000 shares of the stock in a transaction that occurred on Thursday, December 19th. The shares were sold at an average price of $89.77, for a total transaction of $1,346,550.00. Following the completion of the transaction, the director now owns 157,557 shares in the company, valued at $14,143,891.89. This represents a 8.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 48,427 shares of company stock valued at $4,837,801 in the last three months. 4.21% of the stock is owned by corporate insiders.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.